Jiangsu Hengrui Pharma Gets China Nod for Various Drug Trials

MT Newswires Live11-13

Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) and several of its units obtained approval for the clinical trials of various drugs from China's National Medical Products Administration.

The approvals were granted to the company and units Suzhou Shengdi Biopharmaceutical, Shanghai Shengdi Pharmaceutical, and Shanghai Hengrui Pharmaceutical, a Friday bourse filing showed.

The companies plan to conduct trials of SHR-4610 injection, SHR-9839 (sc) for injection, SHR-A2102 for injection, SHR-4849 injection, SHR-7787 injection solution, and HRS-4508 tablets in the near future.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment